Seattle Washington based OncoSenX is raising $5,500,000.00 in New Investment.
Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, OncoSenX is raising $5,500,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Matthew Scholz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About OncoSenX
OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid tumors based on transcriptional activity using a unique Proteo-Lipid Vehicle (PLV) and plasmid DNA. The next generation in cancer therapies will be more targeted with less side effects. At OncoSenX we believe the battle against cancer should be fought with genetic information. Our treatment delivers a simple program that induces apoptosis in cancerous cells. Our approach is a less invasive, more precise intervention for this complex and devastating disease.
To learn more about OncoSenX, visit http://www.oncosenx.com/
Contact:
Matthew Scholz, Chief Executive Officer
206-880-1166
https://www.linkedin.com/in/matthewscholz/
SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved